These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 965101)

  • 1. Comparison of the in vitro bactericidal activity of human serum and leukocytes against bacteroides fragilis and Fusobacterium mortiferum in aerobic and anaerobic environments.
    Bjornson AB; Altemeier WA; Bjornson HS
    Infect Immun; 1976 Sep; 14(3):843-7. PubMed ID: 965101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phagocytosis in vitro by obligate anaerobes.
    Ingham HR; Sisson PR; Tharagonnet D; Selkon JB; Codd AA
    Lancet; 1977 Dec; 2(8051):1252-4. PubMed ID: 73952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of immunoglobulin M antibodies in normal human serum that participate in opsonophagocytosis and intracellular killing of Bacteroides fragilis and Bacteroides thetaiotaomicron by by human polymorphonuclear leukocytes.
    Bjornson AB; Bjornson HS; Kitko BP
    Infect Immun; 1980 Oct; 30(1):263-71. PubMed ID: 6160104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of Bacteroides fragilis O antigens.
    Hofstad T
    Acta Pathol Microbiol Scand B; 1977 Feb; 85B(1):9-13. PubMed ID: 65902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction of Bacteroides fragilis with polymorphonuclear leukocytes and serum factors.
    Casciato DA; Rosenblatt JE; Goldberg LS; Bluestone R
    Infect Immun; 1975 Feb; 11(2):337-42. PubMed ID: 1089602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of Bacteroides fragilis and phagocytes: studies with whole organisms, purified capsular polysaccharide and clindamycin-treated bacteria.
    Wade BH; Kasper DL; Mandell GL
    J Antimicrob Chemother; 1983 Oct; 12 Suppl C():51-62. PubMed ID: 6643341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phagocytic and serum killing of capsulate and non-capsulate Bacteroides fragilis.
    Reid JH; Patrick S
    J Med Microbiol; 1984 Jun; 17(3):247-57. PubMed ID: 6726784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of phagocytosis of E. coli by B. fragilis group--an in vitro study.
    Beena VK; Kumari N; Shivananda PG
    Indian J Pathol Microbiol; 1997 Jul; 40(3):373-6. PubMed ID: 9354011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bactericidal action of human serum on Bacteroides species.
    Rotimi VO; Eke PI
    J Med Microbiol; 1984 Dec; 18(3):355-63. PubMed ID: 6502677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibacterial and bactericidal activity of tinidazole against anaerobic bacteria comparing with metronidazole (author's transl)].
    Ninomiya K; Kobata S; Imamura H; Mochizuki I; Watanabe K
    Jpn J Antibiot; 1976 Mar; 29(3):325-31. PubMed ID: 1271586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Bacteroides asaccharolyticus cells and B. fragilis surface components on serum opsonisation and phagocytosis.
    Jones GR; Gemmell CG
    J Med Microbiol; 1986 Nov; 22(3):225-9. PubMed ID: 3534273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of opsonins for Bacteroides fragilis in immune sera collected from experimentally infected mice.
    Ellis TM; Barrett JT
    Infect Immun; 1982 Mar; 35(3):929-36. PubMed ID: 7068222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Hageman factor by lipopolysaccharides of Bacteroides fragilis, Bacteroides vulgatus, and Fusobacterium mortiferum.
    Bjornson HS
    Rev Infect Dis; 1984; 6 Suppl 1():S30-3. PubMed ID: 6718941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of isolates of Bacteroides to the bactericidal activity of normal human serum.
    Casciato DA; Rosenblatt JE; Bluestone R; Goldberg LS; Finegold SM
    J Infect Dis; 1979 Jul; 140(1):109-13. PubMed ID: 458196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative variability in requirements for opsonization of strains within the Bacteroides fragilis group.
    Bjornson AB; Bjornson HS; Ashraf M; Lang TJ
    J Infect Dis; 1983 Oct; 148(4):667-75. PubMed ID: 6631060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bactericidal mechanisms of polymorphonuclear leukocytes against Bacteroides fragilis: significance of the oxygen-dependent system.
    Nishimura T; Sasada M; Kubo A; Kakita T; Moriguchi T; Uchino H
    Microbiol Immunol; 1987; 31(4):357-66. PubMed ID: 3039317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in opsonophagocytic killing by neutrophils of Bacteroides fragilis associated with animal and laboratory passage: effect of capsular polysaccharide.
    Simon GL; Klempner MS; Kasper DL; Gorbach SL
    J Infect Dis; 1982 Jan; 145(1):72-7. PubMed ID: 7054319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of polymorphonuclear leukocytes with anaerobic bacteria.
    Klempner MS
    Rev Infect Dis; 1984; 6 Suppl 1():S40-4. PubMed ID: 6372036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaction of clinical isolates and typed strains of the family Bacteroidaceae with rabbit anti-Bacteroides sera examined by radial immunodiffusion.
    Shaefer DF; Falkler WA
    J Clin Microbiol; 1983 Jul; 18(1):18-22. PubMed ID: 6136526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the alternative complement pathway by blood culture isolates of Bacteroides fragilis.
    Joiner KA; Hawiger A; Gelfand JA
    Infect Immun; 1981 Oct; 34(1):303-5. PubMed ID: 6795126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.